patients with EGFR-mutation–positive tumors or knownALK receptor tyrosine kinase (ALK) translocation–positive tumors were excluded.
open label
32 hospitals and cancer/medical centers in China, Russia, and Singapore
P3/ two sided and one interim analysis. Hierarchical testing procedure with secondary endpoints
In this predominantly Chinese population with previously treated advanced NSCLC, nivolumab improved OS (ORR and PFS as secondary endpoints) versus docetaxel.